Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
